In patients at high risk for RA, abatacept reduced inflammation and RA development at 6 mo
- PMID: 38950394
- DOI: 10.7326/ANNALS-24-00740-JC
In patients at high risk for RA, abatacept reduced inflammation and RA development at 6 mo
Abstract
Rech J, Tascilar K, Hagen M, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403:850-859. 38364841.
Conflict of interest statement
Comment on
-
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.Lancet. 2024 Mar 2;403(10429):850-859. doi: 10.1016/S0140-6736(23)02650-8. Epub 2024 Feb 13. Lancet. 2024. PMID: 38364841 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical